Pharmabiz23h
CAGE Bio begins phase 2b clinical trial for CGB-500, a breakthrough topical JAK inhibitor for moderate to severe atopic dermatitis
CAGE Bio begins phase 2b clinical trial for CGB-500, a breakthrough topical JAK inhibitor for moderate to severe atopic dermatitis: San Carlos, California Saturday, January 11, 20 ...
The Healthy on MSN1d
8 Reliable Home Remedies for Corns and Calluses
Use these natural, kitchen cabinet cures to get rid of painful corns and calluses. The post 8 Reliable Home Remedies for ...
Researchers identify risk factors for poor prognosis in alopecia areata
Alopecia areata (AA) is a common autoimmune disease that leads to sudden circular hair loss. The clinical course of AA is ...
CAGE Bio Announces Phase 2b Trial for CGB-500 (1% Tofacitinib), a Breakthrough Topical JAK Inhibitor for Moderate to Severe Atopic Dermatitis
SAN CARLOS, CA and FORT WORTH, TX / ACCESSWIRE / January 9, 2025 / CAGE Bio, Inc., a clinical-stage biotechnology company advancing innovative ...
Rolling Out4d
New hope for stubborn eczema sufferers
From atopic dermatitis to contact dermatitis, discover expert-backed treatments and lifestyle changes that can help manage ...
Verywell Health on MSN6d
Dermatitis Types and Treatment Options
Medically reviewed by Jurairat J. Molina, MD Dermatitis is a group of skin problems related to genes, environment, and ...